A 6-Week Dosing Schedule for the Cancer Immunotherapy Pembrolizumab (Keytruda) Receives FDA Approval

On 28 April 2020, the US Food and Drug Administration (FDA) granted accelerated approval for a new regimen of 400 mg every 6 weeks for the immunotherapy drug pembrolizumab (Keytruda), for all cancers for which it had been approved up to that point.
This approval may help reduce how often cancer patients need to visit the hospital while the COVID-19 Pandemic is ongoing.
The approval was based on pharmacokinetic modeling comparing pembrolizumab 400 mg every 6 weeks with the following three different doses: 2 mg/kg every 3 weeks, 200 mg every 3 weeks, and 10 mg/kg every 2 weeks. The pharmacokinetic modeling was supported by the KEYNOTE-555 clinical trial through interim analyses of pharmacokinetics and overall response rate in an enrolled patient group (Cohort B). Cohort B of KEYNOTE-555 was an international, single-arm, multicenter study of patients with advanced melanoma who had not previously received immunotherapy, enrolling 101 patients.
This new dosing regimen was approved under accelerated approval based on pharmacokinetic, exposure–efficacy, and exposure–safety data. Continued approval for this indication may depend on verification and description of clinical benefit in a confirmatory trial.
This application was approved more than five months before the FDA target date.

Sources
fda.gov - 28 April 2020
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.